Product Approval Information
Proper Name: Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant
Tradename: Gardasil
Manufacturer: Merck & Co., Inc, License #0002
Package Insert (PDF - 464 KB) - Approved: September 12, 2008
Patient Information about GARDASIL (PDF - 41 KB)
Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®.
Date: September 12, 2008
Additional Indication: Prevention of vulvar and vaginal cancer
September 12, 2008 Approval Letter
FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers - 9/12/2008
Statistical Review and Evaluation
Information from CDC and FDA on the Safety of Gardasil Vaccine - 7/14/2008
Date: June 12, 2008
Changes to the package insert: To include arthralgia, myalgia, asthenia, fatigue, and malaise in the Adverse Reactions section of the package insert to reflect reports received during post-marketing surveillance, to include corresponding changes to the patient package insert, and to include additional minor editorial changes to the package insert
June 12, 2008 Approval Letter
Date: June 8, 2006
Indication: Vaccination in females 9 to 26 years of age for prevention of the following diseases caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18:
- Cervical cancer
- Genital warts (condyloma acuminata)
and the following precancerous or dysplastic lesions: - Cervical adenocarcinoma in situ (AIS)
- Cervical intraepithelial neoplasia (CIN) grade 2 and grade 3
- Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3
- Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3
- Cervical intraepithelial neoplasia (CIN) grade 1
June 8, 2006 Approval Letter
Executive Summary (PDF - 92 KB)
Questions and Answers
FDA Consumer: New Vaccine Prevents Cervical Cancer
FDA News Release
Get the Facts: HPV (human papillomavirus) - FDA's Office of Women's Health